407
Views
1
CrossRef citations to date
0
Altmetric
Other Disease

Atopic dermatitis 2017: where we were 10–15 years ago in psoriasis

, , ORCID Icon, &
Pages 100-101 | Received 14 Feb 2017, Accepted 08 May 2017, Published online: 30 Jun 2017
 

Abstract

Novel and innovative treatment options for atopic dermatitis (AD) are underway. The recent advancements in understanding AD are reminiscent of the progress made in psoriasis research over a decade ago.

Disclosure statement

Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron.

Dr. Egeberg has received research funding from Pfizer and Eli Lilly, and honoraria as consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma and Janssen Pharmaceuticals.

Dr. Thyssen is supported by an unrestricted grant from the Lundbeck Foundation and has attended an advisory board for Roche and Sanofi-Genzyme, and been a speaker on atopic dermatitis for LEO Pharma.

Mr. No and Ms. Amin do not have any potential conflicts of interest to report.

Additional information

Funding

This article has no funding source.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.